Fibronostics

Call Directions Website Contact the business

Fibronostics Fibronostics is a global diagnostics company, shaping the future of noninvasive diagnostics with artificial intelligence.

We run an in-vitro diagnostics platform that focuses on screening, progression and prognosis of metabolic diseases. Fibronostics'​ LIVERFASt provides early detection and monitoring for patients with NAFLD & NASH. Where the current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool, the LIVERFASt products are easy to use with economical advantages, and have proven clinical value.

It is Poster Day at ACG 2026!Today, Fibronostics is presenting real-world research examining a multimodal, non-invasive ...
10/13/2026

It is Poster Day at ACG 2026!

Today, Fibronostics is presenting real-world research examining a multimodal, non-invasive approach to initiating and monitoring resmetirom therapy in patients with MASH.

Poster P6207
“A Multimodal Noninvasive Approach to Initiation and Monitoring of Resmetirom Therapy in MASH: Update”

Tuesday, October 13
Poster display: 10:30 AM to 4:00 PM CT
Location: Exhibit Hall, Music City Center, Nashville

The analysis explores how LIVERFASt™ and VCTE may support longitudinal monitoring during treatment. Repeated assessment identified improvements in fibrosis scores using both methods, while LIVERFASt™ also supported the monitoring of steatosis regression.

If you are attending ACG, visit Poster P6207 to meet the authors, explore the findings, and discuss the potential value of combining complementary non-invasive tools throughout the treatment journey.

Learn more about LIVERFASt™: https://zurl.co/qhP6C

The ACG Annual Scientific Meeting is underway in Nashville.As the gastroenterology community explores new evidence and e...
10/12/2026

The ACG Annual Scientific Meeting is underway in Nashville.

As the gastroenterology community explores new evidence and evolving clinical pathways, one challenge remains central in MASLD: identifying patients with clinically significant fibrosis before disease progresses unnoticed.

Thank you to everyone who has connected with our team at Booth 2708 or joined us for conversations over dinner. We have truly appreciated the opportunity to exchange perspectives on liver assessment, treatment monitoring, and improving patient pathways.

Join us on Tuesday, October 13, for Poster P6207:
“A Multimodal Noninvasive Approach to Initiation and Monitoring of Resmetirom Therapy in MASH: Update”

The poster explores how LIVERFASt™ and VCTE may support treatment initiation and longitudinal monitoring in patients receiving resmetirom therapy.

We look forward to sharing the findings and continuing the conversation throughout ACG 2026.

MASLD can progress silently, leaving many patients unidentified until fibrosis has reached a more advanced stage.At ACG ...
10/06/2026

MASLD can progress silently, leaving many patients unidentified until fibrosis has reached a more advanced stage.

At ACG 2026, we look forward to sharing new insights into how non-invasive tools may support both treatment initiation and longitudinal monitoring in patients with MASH.

Join us for our poster presentation on Tuesday, 13 October 2026 :
“A Multimodal Noninvasive Approach to Initiation and Monitoring of Resmetirom Therapy in MASH - Update”

The study explores a multimodal approach incorporating LIVERFASt™, vibration-controlled transient elastography, and FIB-4 to assess patients receiving resmetirom therapy.

Visit the Fibronostics team at Booth 2708 to continue the conversation and learn more about comprehensive, blood-based liver assessment.

Explore LIVERFASt™: https://zurl.co/Z5unL

For people with metabolic risk factors, earlier identification of liver disease can help connect them with appropriate e...
10/02/2026

For people with metabolic risk factors, earlier identification of liver disease can help connect them with appropriate evaluation, specialist referral, lifestyle support, treatment consideration, and ongoing monitoring.

LIVERFASt™ provides fibrosis staging, inflammatory activity grading, and steatosis grading from a single routine blood sample, supporting a more complete understanding of liver health.

By making comprehensive liver assessment practical and accessible across routine care settings, LIVERFASt™ can help inform clearer next steps along the patient pathway.

Because earlier insight can help move care forward.

Learn more about LIVERFASt™: https://zurl.co/jUQpD

Advanced liver assessment should not require a complicated workflow.LIVERFASt™ combines 10 commonly available blood biom...
10/01/2026

Advanced liver assessment should not require a complicated workflow.

LIVERFASt™ combines 10 commonly available blood biomarkers with basic patient parameters to provide fibrosis staging, steatosis grading, and inflammatory activity grading from a single routine blood sample.

For laboratories, this means LIVERFASt™ can be integrated into existing workflows without specialised imaging equipment or an additional patient visit.

For clinicians, it provides comprehensive liver insight through a practical, scalable approach that can help support risk stratification and clearer clinical pathways.

Because advanced analytics should make liver assessment more accessible, not more complex.

Learn more about LIVERFASt™: https://zurl.co/3OgQU

Liver health is not static.For patients with MASLD, disease may improve, remain stable, or progress over time depending ...
09/29/2026

Liver health is not static.

For patients with MASLD, disease may improve, remain stable, or progress over time depending on metabolic control, lifestyle changes, and clinical management.

A single result provides a snapshot. Repeatable blood-based assessment can help clinicians evaluate change over time and better understand the direction of a patient’s liver health.

LIVERFASt™ supports longitudinal assessment of fibrosis, inflammatory activity, and steatosis through a practical workflow using a routine blood sample.

Because monitoring change can help inform what happens next.

Learn more about LIVERFASt™:
https://zurl.co/zxz1T

Know the stage. Guide the next step.Fibrosis can progress across a spectrum from F0 to F4, and understanding where a pat...
09/28/2026

Know the stage. Guide the next step.

Fibrosis can progress across a spectrum from F0 to F4, and understanding where a patient sits on that spectrum can help inform appropriate clinical decisions.

LIVERFASt™ provides biopsy-aligned fibrosis staging, together with steatosis and inflammatory activity assessment, from a single routine blood sample.

This comprehensive insight can help support risk stratification and determine whether further evaluation, specialist referral, lifestyle intervention, or ongoing monitoring may be appropriate.

Because clearer staging can help create clearer clinical pathways.

Learn more about LIVERFASt™: https://zurl.co/cRzYn

When screening patients at metabolic risk, a test must do more than identify those already at obvious risk.Published evi...
09/24/2026

When screening patients at metabolic risk, a test must do more than identify those already at obvious risk.

Published evidence has shown that LIVERFASt™ provides higher sensitivity than FIB-4 for identifying advanced fibrosis in patients with MASLD, including those with type 2 diabetes.

Greater sensitivity can help identify more patients who may benefit from further assessment.

Explore the evidence: https://zurl.co/o2aio

Liver assessment is most valuable when the result helps inform what happens next.For patients at risk of MASLD, that nex...
09/22/2026

Liver assessment is most valuable when the result helps inform what happens next.

For patients at risk of MASLD, that next step may include further evaluation, specialist referral, lifestyle intervention, treatment consideration, or longitudinal monitoring.

LIVERFASt™ provides fibrosis staging, steatosis assessment, and inflammatory activity assessment to help support clearer clinical pathways.

Because actionable insight should help move patient care forward.

Find out more: https://zurl.co/2TnKM

From Paris to New Orleans and Orlando, September has been a month of meaningful connections and valuable conversations a...
09/21/2026

From Paris to New Orleans and Orlando, September has been a month of meaningful connections and valuable conversations across liver science, primary care, gastroenterology, and GI nursing.

Thank you to everyone who met with the Fibronostics teams at Paris MASH, the LANP Annual Conference, and the FGS/SGNA Joint Annual Meeting.

While each meeting brought together different perspectives, one goal connected them all: recognising liver risk earlier and helping patients move towards the right next step in care.

These conversations also gave us the opportunity to share how LIVERFASt™ provides insight into fibrosis, inflammatory activity, and steatosis from a single routine blood sample, supporting a more complete understanding of liver health.

We leave these meetings encouraged, inspired, and looking forward to continuing the collaboration.

Learn more: https://zurl.co/ekKUP

Address

274 E. Eau Gallie Boulevard , #346 Indian Harbour Beach
Orlando, FL
32937

Telephone

+18885521603

Website

Alerts

Be the first to know and let us send you an email when Fibronostics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Fibronostics:

Shortcuts

Share

Category